Axsome Therapeutics, Inc. filed a current report on August 10, 2026, announcing its financial results for the three months ended June 30, 2026, and providing an update on company operations.

Key Highlights

  • Reporting period: Financial results cover the three months ended June 30, 2026.
  • Report date: The press release and current report were both dated August 10, 2026.
  • Corporate presentation updated: The company posted an updated corporate presentation to its website on August 10, 2026, filed as Exhibit 99.2.
  • Exchange listing: Common Stock (par value $0.0001 per share) trades on the Nasdaq Global Market under the symbol AXSM.
  • Signatory: The report was signed by Herriot Tabuteau, M.D., President and Chief Executive Officer.

Axsome Therapeutics Discloses Q2 2026 Results and Updated Corporate Presentation

According to the filing, Axsome Therapeutics, Inc. (Nasdaq Global Market: AXSM) issued a press release on August 10, 2026, announcing its financial results for the second quarter ended June 30, 2026. The press release, attached as Exhibit 99.1, also included an operational update from the company. The filing was made under Item 2.02, covering Results of Operations and Financial Condition.

The filing notes that the information included under Item 2.02, including Exhibit 99.1, "shall not be deemed 'filed' for the purposes of Section 18 of the Securities Exchange Act of 1934" and is not automatically incorporated by reference into other filings unless specifically referenced. This characterization is the company's own, as stated in the report.

Separately, under Item 8.01, the company disclosed that it updated its corporate presentation on August 10, 2026, and posted it to the company's website. That presentation was filed as Exhibit 99.2 and, unlike the press release, is incorporated by reference into the current report. The filing was signed by Herriot Tabuteau, M.D., in his capacity as President and Chief Executive Officer of Axsome Therapeutics, Inc., a Delaware corporation headquartered at One World Trade Center, 29th Floor, New York, New York 10007.

What Was Disclosed

Axsome Therapeutics filed an 8-K on August 10, 2026, furnishing a press release with Q2 2026 financial results and operational updates, and filing an updated corporate presentation posted to the company's website on the same date.